Adrenal Insufficiency Clinical Trial
Official title:
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Healthy Children and Adolescent
Verified date | February 2019 |
Source | Nationwide Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Bone disease and adrenal suppression are two of the many side effects of steroid use in
pediatrics. Evidence has shown that adrenocorticotropic hormone (ACTH) protects against the
adverse bone effects of steroids in animals and in vitro models, but this has not yet been
evaluated in humans. The proposed mechanism in these studies is that ACTH stimulates
osteoblasts in bone to release Vascular Endothelial Growth Factor (VEGF), which increases the
vascularity in high risk areas of bone. This can potentially be protective against
osteonecrosis and osteopenia, which can lead to bone fractures if not prevented. The VEGF
release can also be used to demonstrate that an administration of exogenous ACTH occurred.
This could be important in diagnosing adrenal insufficiency (AI). One of the tests to assess
central AI is the low-dose ACTH stimulation test (LDAST). This test has a high rate of false
positive results due to technical limitations. However, if an ACTH-stimulated VEGF level can
be measured during the test as a marker of the test being done properly, it will allow for
proper interpretation of the results (and identification of a false positive), which will
reduce the number of patients being incorrectly diagnosed with central AI.
This study will recruit ten healthy children and adolescents, ages 9-18, to assess the
effects of ACTH on VEGF levels. The investigators will measure the response of VEGF and
cortisol to an administration of a low dose and high dose of cosyntropin (the synthetic ACTH
analog used in this test). The hypothesis of this study is that VEGF and cortisol will both
increase after administration of cosyntropin. At this time, no other studies have
demonstrated that VEGF is responsive to ACTH in humans. If the hypothesis is correct, the
results will have two main implications. VEGF can be used as a marker of ACTH administration
during the LDAST to identify false positive tests. Secondly, this will help further research
into whether ACTH can be used to protect against bone disease in high-dose steroid-treated
patients. Further studies can be done to assess whether this effect will be the same in
patients with AI or steroid-induced adrenal suppression.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 31, 2019 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 9 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Subjects will be between the ages of 9-18 years old on the day of testing Exclusion Criteria: - Currently taking any medication other than over-the-counter medications (over-the-counter medications will be stopped on the day of the study) - Steroid use within the prior six months (including IV, oral, inhaled, and intranasal steroids) - Oral Contraceptive Pill use within the prior six months - Any chronic medical conditions - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Nationwide Children's Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Nationwide Children's Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference between VEGF levels at baseline and the peak VEGF level after low dose cosyntropin administration in healthy children and adolescents | Prior to administering Cosyntropin, a VEGF level will be obtained. 1 mcg Cosyntropin will be administered at t=0, then VEGF will be measured at 30 and 60 minutes. The investigators will run a comparison on the peak plasma VEGF level (the higher of the 30 and 60 minute level) after low dose stimulation compared to baseline VEGF levels. | From t=0 minutes to t=60 minutes (1 hour total) | |
Secondary | Difference between VEGF levels at baseline and the peak VEGF level after high dose cosyntropin administration in healthy children and adolescents | After the 60 minute blood draw, a high dose (250 mcg) of Cosyntropin will be given. VEGF levels will be obtained every 30 minutes for another 2 hours (t=90, 120,150,180 min). The investigators will run a comparison on the peak plasma VEGF level (the highest of the 90, 120,150,180 minute levels) after high dose stimulation compared to baseline VEGF levels. | From t=60 minutes to t=180 minutes (2 hours total) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03282487 -
Optimising Steroid Replacement in Patients With Adrenal Insufficiency
|
Phase 4 | |
Not yet recruiting |
NCT06435481 -
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
|
Phase 4 | |
Not yet recruiting |
NCT05716607 -
Treatment Study in Patients Treated With Both Insulin & Hydrocortisone
|
N/A | |
Recruiting |
NCT03399383 -
Adherence in Chronic Adrenal Insufficiency
|
N/A | |
Completed |
NCT01428336 -
Value of 25 mcg Cortrosyn Stimulation Test
|
N/A | |
Completed |
NCT00851942 -
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
|
Phase 4 | |
Withdrawn |
NCT00368381 -
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
|
Phase 4 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Completed |
NCT03013166 -
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
|
||
Enrolling by invitation |
NCT02282150 -
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
|
Phase 4 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT03000231 -
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
|
||
Completed |
NCT01960530 -
An Investigational Study of Hydrocortisone
|
Phase 1 | |
Completed |
NCT00552487 -
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
|
N/A | |
Completed |
NCT00575341 -
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
|
Phase 3 | |
Completed |
NCT00471900 -
Six Months DHEA Treatment in Female Adrenal Failure
|
N/A | |
Completed |
NCT03294876 -
Rheumatoid Arthritis Adrenal Recovery Study
|
||
Recruiting |
NCT05639127 -
The Treatment of Adrenal Crisis With Inhaled Prednisolone
|
Early Phase 1 | |
Completed |
NCT04488432 -
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant
|